141 related articles for article (PubMed ID: 23756764)
1. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
Ganesan P; Piha-Paul S; Naing A; Falchook G; Wheler J; Fu S; Hong DS; Kurzrock R; Janku F; Laday S; Bedikian AY; Kies M; Wolff RA; Tsimberidou AM
Invest New Drugs; 2014 Apr; 32(2):279-86. PubMed ID: 23756764
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
Ganesan P; Piha-Paul S; Naing A; Falchook G; Wheler J; Janku F; Zinner R; Laday S; Kies M; Tsimberidou AM
Invest New Drugs; 2013 Dec; 31(6):1505-13. PubMed ID: 23982248
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
Said R; Ye Y; Hong DS; Naing A; Falchook G; Fu S; Wheler JJ; Piha-Paul S; Tsimberidou AM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):575-81. PubMed ID: 26825327
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
Said R; Kakadiaris E; Piha-Paul S; Fu S; Falchook G; Janku F; Wheler JJ; Zinner R; Hong DS; Kurzrock R; Tsimberidou AM
Cancer Chemother Pharmacol; 2016 May; 77(5):1097-102. PubMed ID: 27085994
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
Kumar SK; Jett J; Marks R; Richardson R; Quevedo F; Moynihan T; Croghan G; Markovic SN; Bible KC; Qin R; Tan A; Molina J; Kaufmann SH; Erlichman C; Adjei AA
Invest New Drugs; 2013 Oct; 31(5):1201-6. PubMed ID: 23887852
[TBL] [Abstract][Full Text] [Related]
7. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
8. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Martín-Liberal J; López-Pousa A; Broto JM; Cubedo R; Gallego O; Brendel E; Tirado OM; del Muro XG
Invest New Drugs; 2014 Apr; 32(2):287-94. PubMed ID: 23801301
[TBL] [Abstract][Full Text] [Related]
10. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Bilen MA; Fu S; Falchook GS; Ng CS; Wheler JJ; Abdelrahim M; Erguvan-Dogan B; Hong DS; Tsimberidou AM; Kurzrock R; Naing A
Cancer Chemother Pharmacol; 2015 Apr; 75(4):869-74. PubMed ID: 25666183
[TBL] [Abstract][Full Text] [Related]
12. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
15. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Kim R; Prithviraj GK; Shridhar R; Hoffe SE; Jiang K; Zhao X; Chen DT; Almhanna K; Strosberg J; Campos T; Shibata D
Radiother Oncol; 2016 Feb; 118(2):382-6. PubMed ID: 26861740
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Puzanov I; Sosman J; Santoro A; Saif MW; Goff L; Dy GK; Zucali P; Means-Powell JA; Ma WW; Simonelli M; Martell R; Chai F; Lamar M; Savage RE; Schwartz B; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):159-68. PubMed ID: 25294187
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
Sullivan RJ; Ibrahim N; Lawrence DP; Aldridge J; Giobbie-Hurder A; Hodi FS; Flaherty KT; Conley C; Mier JW; Atkins MB; McDermott DF
Oncologist; 2015 Jun; 20(6):617-8. PubMed ID: 25986244
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
